Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

Nature

Volumn 455, Issue 7215, 2008, Pages 967-970

  Janoueix Lerosey, Isabelle ^a,b   Lequin, Delphine ^a,b   Brugières, Laurence ^c   Ribeiro, Agnès ^a   De Pontual, Loïc ^d   Combaret, Valérie ^e   Raynal, Virginie ^a,b   Puisieux, Alain ^e,f,g   Schleiermacher, Gudrun ^a,b   Pierron, Gaëlle ^a   Valteau Couanet, Dominique ^c   Frebourg, Thierry ^h   Michon, Jean ^a   Lyonnet, Stanislas ^d   Amiel, Jeanne ^d   Delattre, Olivier ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Centre Léon Bérard FNCLCC Laboratoire de Recherche Translationnelle

^f INSERM   (France)

^g UNIVERSITÉ DE LYON   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

CANCER; COMPARATIVE STUDY; DISEASE TREATMENT; DNA; ENZYME ACTIVITY; GENE EXPRESSION; GENETICS; GENOME; HYBRIDIZATION; MUTATION; NERVOUS SYSTEM DISORDER; TUMOR;

ARTICLE; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE LOCUS; MUTATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 54049149961     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07398     Document Type: Article

References (27)

1. Maris, J. M., Hogarty, M. D., Bagatell, R. & Cohn, S. L. Neuroblastoma. Lancet 369, 2106-2120 (2007).
2. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nature Rev. Cancer 3, 203-216 (2003).
3. Tonini, G. P., Longo, L., Coco, S. & Perri, P. Familial neuroblastoma: a complex heritable disease. Cancer Lett. 197, 41-45 (2003).
4. Trochet, D. et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74, 761-764 (2004).
5. Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphomakinase in the pathogenesis of cancer. Nature Rev. Cancer 8, 11-23 (2008).
6. Galkin, A. V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl Acad. Sci. USA 104, 270-275 (2007).
7. Li, R.& Morris, S. W. Development of anaplastic lymphoma (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev. 28, 372-412 (2008).
8. Fix, A. et al. Characterization of amplicons in neuroblastoma. High-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosom. Cancer 47, 819-834 (2008).
9. Schwab, M. et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308, 288-291 (1984).
10. Lamant, L. et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156, 1711-1721 (2000).
11. Osajima-Hakomori, Y. et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 167, 213-222 (2005).
12. Miyake, I. et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21, 5823-5834 (2002).
13. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
14. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
15. Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007).
16. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395 (2008).
17. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994).
18. Griffin, C. A. et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2276-2280 (1999).
19. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448, 561-566 (2007).
20. Chiarle, R. et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101, 1919-1927 (2003).
21. Fujimoto, J. et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl Acad. Sci. USA 93, 4181-4186 (1996).
22. Hubbard, S. R. Juxtamembrane autoinhibition in receptor tyrosine kinase. Nature Rev. Mol. Cell Biol. 5, 464-471 (2004).
23. Renneville, A. et al. Cooperating gene mutations in acute myeloid leukaemia: a review of the literature. Leukemia 22, 915-931 (2008).
24. Gilliland, G. & Griffin, G. The roles of FLT3 in hematopoiesis and leukaemia. Blood 100, 1532-1542 (2002).
25. Fröhling, S. et al. Identification of driver and passenger mutations of FLT3 by highthroughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12, 501-513 (2007).
26. Chiarle, R. et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature. Med. 14, 676-680 (2008).
27. Vincent-Salomon, A., Raynal, V., Lucchesi, C., Gruel, N. & Delattre, O. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809 (2008).